Table 4.
Selected Chemotherapy Regimens in Relapsed/Refractory AML
| Regimen | N | Age (Median and Range) | Adverse Cytogenetics | CR | LFS (Median) | OS [median (95% CI)] | Ref. |
|---|---|---|---|---|---|---|---|
| FLAM | 62 | 58 (23–73) | 50% | 75% in first relapse patients; 15% in primary refractory patients | 11 months (2.5–26.5+) | 8 months (0.3–30+) | 32 |
| GCLAC | 50 | 53 (19–69) | 40% | 46% | n/a | 9 months (5.2–13) | 31 |
| Elacytarabine | 191 | 62 (22–89) | 40% | 23% | 5.1 months (3.3–7.8) | 3.5 months (2.8–4.8) | 34 |
| Vosaroxin + cytarabine | 356 | 64 (20–80) | 24% | 30% | 11 months (8.3–NR) | 7.5 months (6.4–8.5) | 33 |
CR, complete remission; LFS, leukemia-free survival; OS, overall survival; N, numbers of patients; FLAM, flavopiridol, cytarabine, mitoxantrone; GCLAC, granulocyte colony-stimulating factor, clofarabine, cytarabine; NR, not reached; n/a, not available.